Middle East and Africa Cell Line Development Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Type, Product, Application

The Middle East and Africa cell line development market is expected to reach US$ 626.07million in 2027 from US$ 247.84million in 2019. The market is estimated to grow at a CAGR of 12.4% from 2020-2027.

The growth of this market is attributed to the increasing focus on the research and development activities related to cell line development and a high prevalence of cancer in the region. However, several issues related to the cell line development are hindering the market growth.

Significant growth of the cell line development market in the Middle East and Africa is mainly attributed to increased healthcare expenditure as well as initiatives by the governments of various countries to boost research and development activities related to life sciences. The availability of technologically advanced devices and research facilities, and rising number of conferences on synthetic biology and genetic engineering are other factors contributing to the growth of the market in this region. With the emphasis on industrialization, the UAE is encouraging start-ups and research enthusiasts in the country by providing them with potential platforms, research facilities, and other conveniences to develop cell line development innovations. DUBIIOTECH - i.e., Dubai Biotechnology and Research Park - is a science and business park dedicated to the biotechnology and biopharmaceutical industry modeled on a free-zone concept. The biotech park assists government-funded research and development projects through world-class infrastructure that includes services and commodities for R&D labs, research and academic institutes, manufacturing companies, and start-ups, along with the organizations from supporting and convergent industries.

Moreover, with the increasing number of research projects, institutes such as King Abdullah University of Science and Technology are contributing significantly to research and technology developments in the region. Synthetic biology, next-generation sequencing, and personalized medicines are among the emerging fields in the region. Most individual researchers and start-up companies are now focusing on developing innovative products through these technologies in Saudi Arabia.

COVID-19 has dramatically impacted clinical trials due to site closures, stay-at-home orders, and supply chain issues, among other barriers. The pandemic has amplified a few of the difficulties that have been a part of clinical trials in low-middle-income countries since long. A few of the lower-middle-income countries have issued guidance or directives pertaining to clinical research during the pandemic, which are similar to those issued by the FDA and the European Medicines Agency. However, as most countries have not issued specific COVID-19 guidance for clinical trials, there are uncertainties around the study protocol, which are leading to often delays in regulatory approvals in these countries, thereby limiting the cell lone development market growth.

Based on type, the Middle East and Africa cell line development market is segmented into a primary cell lines, hybridomas, continuous cell lines, and recombinant cell lines. The recombinant cell lines segment held the largest market share in 2019, whereas the hybridomas segment is anticipated to register the highest CAGR in the market during the forecast period.

The Middle East and Africa cell line development market, by product, is segmented into equipment, and media & reagent. The media & reagent segment held the largest share of the market in 2019, and it is anticipated to register the highest CAGR in the market from 2020 to 2027.

Based on application, the Middle East and Africa cell line development market is segmented into drug discovery, bioproduction, and tissue engineering. The bioproduction segment held the largest market share in 2019. However, the drug discovery segment is anticipated to register the highest CAGR in the market during 2020-2027.

A few of the primary and secondary sources referred to while preparing the report on the Middle East and Africa cell line development market are the Cancer Association of South Africa (CANSA) and Dubai Health Authority (DHA).